You are here

  • Home
  • Archive
  • Volume 20, Issue 5
  • Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Randomised controlled trial
Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome

https://doi.org/10.1136/ebmed-2015-110253

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests PPT is a consultant for Amgen, AstraZeneca, Kowa, Merck and Novartis. PPT is also involved in speaker's bureau activities for Amarin, AstraZeneca, Genzyme, GSK, Kowa and Merck.

    • Provenance and peer review Commissioned; internally peer reviewed.